School of Medicine
Showing 301-400 of 707 Results
-
Kristina Kudelko
Clinical Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
Current Research and Scholarly InterestsDrugs and toxins-associated pulmonary arterial hypertension, clinical outcomes research, acute kidney injury in pulmonary arterial hypertension
-
Ellen Kuhl
Catherine Holman Johnson Director of Stanford Bio-X, Walter B Reinhold Professor in the School of Engineering, Professor of Mechanical Engineering and, by courtesy, of Bioengineering
Current Research and Scholarly Interestscomputaitonal simulation of brain development, cortical folding, computational simulation of cardiac disease, heart failure, left ventricular remodeling, electrophysiology, excitation-contraction coupling, computer-guided surgical planning, patient-specific simulation
-
Calvin Kuo
Maureen Lyles D'Ambrogio Professor
Current Research and Scholarly InterestsWe study cancer biology, intestinal stem cells (ISC), and angiogenesis. We use primary organoid cultures of diverse tissues and tumor biopsies for immunotherapy modeling, oncogene functional screening and stem cell biology. Angiogenesis projects include blood-brain barrier regulation, stroke therapeutics and anti-angiogenic cancer therapy. ISC projects apply organoid culture and ko mice to injury-inducible vs homeostatic stem cells and symmetric division mechanisms.
-
Christin S Kuo
Assistant Professor of Pediatrics (Pulmonary Medicine)
BioDr. Christin Kuo is a physician-scientist in the Department of Pediatrics. The ultimate goal of her research is to integrate a cellular and molecular understanding of pulmonary neuroendocrine cells (PNECs) to discover new approaches for diagnosing and treating diverse respiratory conditions associated with NE cell dysfunction and excessive proliferation, including neuroendocrine tumors. Abnormal PNECs are found in neuroendocrine cell hyperplasia of infancy (NEHI), pulmonary carcinoids, large cell neuroendocrine carcinoma, and small cell lung cancer. Her innovative approaches to studying the development and molecular diversity of rare but fascinating neurosensory cells with single cell precision, have led to fundamental discoveries. Her lab’s current research aims to apply this knowledge to understanding diverse human pulmonary neuroendocrine cell disorders using interdisciplinary approaches. Dr. Kuo is a Maternal and Child Health Research Institute Faculty Scholar.
-
WILLIAM T. KUO, MD, FSIR, FCCP, FSVM, FACR, FCIRSE
Professor of Radiology (Interventional Radiology)
Current Research and Scholarly Interests1) LASER-ASSISTED AND COMPLEX IVC FILTER RETRIEVAL
2) CATHETER-DIRECTED THERAPY FOR ACUTE PULMONARY EMBOLISM
3) INTERNATIONAL PE REGISTRY
4) IVC FILTER REGISTRY
5) ENDOVASCULAR TREATMENT OF CAVAL AND DEEP VENOUS THROMBOSIS -
Richard Lafayette
Professor of Medicine (Nephrology)
Current Research and Scholarly InterestsWe are continuing to grow a glomerulonephritis cohort study, including immunologic characterization. We have completed interventional studies of preeclampsia exploring the nitric oxide, endothelin system and effects on glomerular function and morphometry. We continue to recruit patients for treatment and observational studies of glomerular disease, including FSGS, membranous and particularly IgA nephropathy. We also are actively studying renal disease in systemic amyloidosis.
-
Philip W. Lavori
Professor of Biomedical Data Science, Emeritus
Current Research and Scholarly InterestsBiostatistics, clinical trials, longitudinal studies, casual inference from observational studies, genetic tissue banking, informed consent. Trial designs for dynamic (adaptive) treatment regimes, psychiatric research, cancer.
-
Laura C. Lazzeroni, Ph.D.
Professor (Research) of Psychiatry and Behavioral Sciences and, by courtesy, of Biomedical Data Science
Current Research and Scholarly InterestsStatistics/Data Science. I develop & apply models, methods & algorithms for complex data in medical science & biology. I am also interested in the interplay between fundamental statistical properties (e.g. variability, bias, p-values) & how scientists actually use & interpret data. My work in statistical genetics includes: the invention of Plaid bi-clustering for gene expression data; methods for twin, association, & family studies; multiple testing & estimation for high dimensional arrays.
-
Anson Lee
Assistant Professor of Cardiothoracic Surgery (Adult Cardiac Surgery)
BioDr. Anson Lee specializes in the surgical treatment of all heart diseases, including ischemic heart disease, structural heart disease, aortic disease, and arrhythmias. He has practiced cardiothoracic surgery at Stanford since 2015. Dr. Lee has a special interest in the surgical treatment of abnormal heart rhythms and minimally invasive techniques to treat heart disease.
-
David Lee, MD
Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly Interests1. Novel treatments and devices for the treatment of valvular disease
2. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy
3. Novel approaches to coronary revascularization
4. Closure devices for atrial septal defects and patent foramen ovale
5. Novel treatments for hypertension -
Jason T. Lee, MD
Professor of Surgery (Vascular Surgery)
Current Research and Scholarly InterestsDr. Lee is the Principal Investigator on several clinical trials examining therapeutic strategies for management of complex aortic aneurysm disease as well as aortic dissection.
Dr. Lees clinical interests include:
Endovascular repair of abdominal/thoracic aneurysms and dissections
Fenestrated and Branch Repair of the thoracic, thoracoabdominal, and abdominal aneurysms
Carotid stenting
Thoracic outlet syndrome
Vascular disorders in high-performance athletes -
Jennifer Lee
Professor of Medicine (Endocrinology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsI am a healthcare lead and physician scientist for innovation, R&D, and advanced analytics, and oversee these aspects at VA Palo Alto/VHA, within Stanford-VA relationship. The VA has the US's largest health care system and longest running EHR. I prioritize enabling multiple partners (industry, government, academia, foundations), to innovate/R&D in the VA health care system. We prioritize mentoring students from various Schools to become future leaders in R&D, innovation, and healthcare.
-
Marc Leon (aka Hongliang Liang) MD, PhD
Clinical Assistant Professor, Cardiothoracic Surgery
BioMarc Leon (also known as Hongliang Liang), M.D., Ph.D., previously served as Chief Surgeon, Associate Professor of Cardiovascular Surgery, and Director of the Division of Coronary Artery Surgery at Xijing Hospital in Xi'an, China. Currently, he is a Clinical Assistant Professor in the Department of Cardiothoracic Surgery at Stanford Hospital. Dr. Leon is a surgeon member of the Society of Thoracic Surgeons (STS), the International Society of Heart and Lung Transplantation (ISHLT), and the Chinese American Academy of Cardiology (CAAC). His clinical and research expertise includes the surgical management of cardiopulmonary failure, heart valve disease, and ischemic heart disease, along with the application of stem cell therapy for myocardial infarction. Additionally, Dr. Leon is actively engaged in exploring the application of artificial intelligence in the field of cardiovascular diseases.
-
Lawrence Leung
Maureen Lyles D'Ambrogio Professor in the School of Medicine
Current Research and Scholarly InterestsOur long term interest is to have a better understanding of the natural antithrombotic pathways and the pathophysiology of vascular thrombosis. We have focused on thrombin, the key enzyme in the blood clotting cascade.Our goal is to develop new antithrombotic agents and devise new diagnostic tests for vascular thrombotic disorders.
-
Marc Levenston
Associate Professor of Mechanical Engineering and, by courtesy, of Radiology (Radiological Sciences Laboratory)
Current Research and Scholarly InterestsMy lab's research involves the function, degeneration and repair of musculoskeletal soft tissues, with a focus on meniscal fibrocartilage and articular cartilage. We are particularly interested in the complex interactions between biophysical and biochemical cues in controlling cell behavior, the roles of these interactions in degenerative conditions such as osteoarthritis, and development of tissue engineered 3D model systems for studying physical influences on primary and progenitor cells.
-
Craig Levin
Professor of Radiology (Molecular Imaging Program at Stanford/Nuclear Medicine) and, by courtesy, of Physics, of Electrical Engineering and of Bioengineering
Current Research and Scholarly InterestsMolecular Imaging Instrumentation
Laboratory
Our research interests involve the development of novel instrumentation and software algorithms for in vivo imaging of cellular and molecular signatures of disease in humans and small laboratory animal subjects. -
Eldrin F. Lewis, MD, MPH
Simon H. Stertzer, MD, Professor
BioDr. Lewis is a board-certified, fellowship-trained specialist in cardiovascular medicine. He is the chief of the Division of Cardiovascular Medicine and a professor of cardiovascular medicine.
Dr. Lewis is an esteemed clinician-scientist who specializes in the care of patients with advanced heart failure. He is an internationally recognized expert on heart failure, heart transplant, and quality of life for heart failure patients. He cares deeply about his patients as well as his colleagues, the hospital, and the School of Medicine. Dr. Lewis is committed to diversity and inclusion, as well as expanding Stanford clinical research initiatives.
A fundamental principle of Dr. Lewis’ practice is his belief that “there is more to life than death,” that cardiovascular care should go beyond helping patients survive to also helping them enjoy the best possible quality of life.
Dr. Lewis has deep expertise in conducting clinical trials examining diagnostic and therapeutic approaches to heart failure. He has done innovative work to create systems for incorporating quality of life measures for cardiovascular patients into electronic health records. This research has received support from the National Heart, Lung and Blood Institute and the National Institutes of Health.
Much of his quality of life research has focused on patient-reported outcomes. Dr. Lewis emphasizes the importance of looking at how a disease, whether chronic or acute, impacts people’s ability to function and perform their activities of daily living. Strategies to improve patients’ well-being focus not only on their physical symptoms but also on depression, anxiety, exercise capacity, and ability to function in daily living.
Dr. Lewis’ commitment to expanding clinical research initiatives will give patients more opportunities to participate in the clinical trials and access the latest care strategies that can translate into better outcomes. The goal is early access to the most advanced technology, pharmacology, and device therapy that can change outcomes for the better. He also envisions forming closer partnerships with community cardiologists and capitalizing further on Stanford’s proximity to and unique relationships with the digital technology leaders of Silicon Valley to enhance the use of digital technology for monitoring patients, optimizing treatment, and tracking outcomes.
He has authored nearly 200 articles published in peer-reviewed journals including the New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, JAMA Cardiology, JAMA Internal Medicine, and many more. He is also on multiple editorial boards for cardiovascular journals and was an associate editor for Circulation–Heart Failure. In addition, he is an author of professional society clinical practice guidelines and scientific statements from both the American Heart Association (AHA) and the Food and Drug Administration.
Dr. Lewis’ honors for clinical care, scholarship, and research include the Joel Gordon Miller Award for community service and leadership from the University of Pennsylvania School of Medicine. He also was one of the first recipients of the Minority Faculty Development Award, which recognizes the research potential of young physicians. Dr. Lewis has received a grant from the Robert Wood Johnson Foundation to study the role of quality of life assessment in clinical decision making in patients with heart failure.
He is a fellow of the American College of Cardiology and the National American Heart Association (AHA) Research Committee. In addition, Dr. Lewis was as a member of the AHA Founders Affiliate Board of Directors, chair of the Council on Clinical Cardiology, and research chair of the Association of Black Cardiologists. He also serves on scientific committees to review grants for the AHA and on the FDA Task Force for the Standardization of Definitions for Endpoint Events in Cardiovascular Trials. -
Caiyun Grace Li
Member, Cardiovascular Institute
Current Role at StanfordSenior Research Scientist
-
Jin Billy Li
Professor of Genetics
Current Research and Scholarly InterestsThe Li Lab is primarily interested in RNA editing mediated by ADAR enzymes. We co-discovered that the major function of RNA editing is to label endogenous dsRNAs as "self" to avoid being recognized as "non-self" by MDA5, a host innate immune dsRNA sensor, leading us to pursue therapeutic applications in cancer, autoimmune diseases, and viral infection. The other major direction of the lab is to develop technologies to harness endogenous ADAR enzymes for site-specific transcriptome engineering.
-
David Liang, MD, PhD
Professor of Medicine (Cardiovascular) at the Stanford University Medical Center, Emeritus
BioStanford researchers are creating a micro-device that physicians could guide through the body to help diagnose and treat clogged arteries and other diseases. Tethered to the outside world by a thin wire, a tiny machine creeps through blood vessels, searching out deadly plaques and obliterating them with a zap of a laser. While a laser will come later, for now David Liang, MD, PhD, is focusing on a tiny eye that could give physicians an unprecedented view into blood vessels.
-
Ronglih Liao
Douglass M. and Nola Leishman Professor of Cardiovascular Disease
BioDr. Liao is a Professor of Medicine and co-Director of Stanford Cardiac Amyloid Center. The major goal of her research program focuses on understanding the mechanisms that underlie the pathophysiology of heart failure and developing novel treatments to combat this process. Her laboratory has played an international leading role in the study of amyloid light chain (AL) cardiomyopathy, a rare and fatal form of cardiovascular disease. We have described the underlying pathophysiologic basis for amyloid cardiomyopathy and found that the circulating amyloidogenic light chain proteins that characterize this disease directly result in a specific cardiotoxic response. Consequently, our research work has redefined AL cardiomyopathy and has raised new treatment approaches. More recently, her research efforts have expanded to include transthyretin (ATTR) cardiac amyloidosis.
In line with her goal of revealing novel therapeutic strategies for patients with cardiovascular disease, our efforts have also focused on characterizing and harnessing endogenous cardiac regenerative mechanisms. Her laboratory initially demonstrated the therapeutic potential of exogenous primitive muscle cells delivered to the injured heart. This work was among the earliest milestones in the field and served as the basis for an international trial of cell-based therapy. Subsequently, Liao lab identified and characterized a population of cardiac progenitor cells and its relationship and dynamic activity following cardiac injury in the adult heart. Her laboratory aims to reveal the molecular mechanisms regulating the endogenous regenerative capacity of the heart and to harness such repair mechanisms for the treatment of cardiovascular disease. Dr. Liao has lectured extensively on both amyloid cardiomyopathy and stem cell biology, and have maintained a history of independent NIH funding in these areas for more than two decades.
Over the course of her academic career, she has taken the greatest pride in mentoring the next generation of scientists. Dr. Liao has had the privilege to supervise several dozen students, postdoctoral fellows, and junior faculty, many of whom have gone on to independent academic careers at the highest institutions. Her contribution to the advancement of scientific knowledge also includes lecturing at various university and academic institutions as well as at scores of conferences and symposia locally, nationally, and internationally. -
Michaela Liedtke
CKD Family Professor
Current Research and Scholarly Interests1) Design of phase I/II trials for the treatment of Multiple Myeloma and Amyloidosis
2) Conduct of clinical trials to improve the treatment of patients with acute lymphoblastic leukemia (ALL)
3) Outcomes research using clinical databases for patients with Multiple Myeloma and Amyloidosis -
Bryant Lin
Clinical Professor, Medicine - Primary Care and Population Health
Current Research and Scholarly Interests-Digital Health
-Medical device design, prototyping, testing and clinical trials
-Behavioral determinants of chronic disease
-Novel diagnostic processes for medical mysteries
-Asian Health
-Medical Humanities and Arts
-Medical Technology -
Margaret Chin-Chin Lin
Clinical Associate Professor, Radiology
BioDr. Margaret Lin is a board certified radiologist with subspecialty training in thoracic and cardiovascular imaging. Dr. Lin specializes in diseases affecting the lungs and airways, including cancer, infection, and interstitial and inhalational lung diseases. Dr. Lin has a passion for resident education and development of curricula and new educational tools. She is the current Program Director for the Diagnostic Radiology Residency Program.
-
Michael Lin
Professor of Neurobiology and of Bioengineering
Current Research and Scholarly InterestsOur lab applies biochemical and engineering principles to the development of protein-based tools for investigating biology in living animals. Topics of investigation include fluorescent protein-based voltage indicators, synthetic light-controllable proteins, bioluminescent reporters, and applications to studying animal models of disease.
-
Yihan Lin, MD MPH
Clinical Assistant Professor, Cardiothoracic Surgery
BioDr. Lin is a cardiothoracic surgeon and clinical assistant professor in the Department of Cardiothoracic Surgery at Stanford University School of Medicine. She provides the complete spectrum of surgical care for cardiac conditions, including ischemic heart disease, structural heart disease, aortic disease, and arrhythmias.
Dr. Lin's research is focused on surgical education and global disparities in surgical care. She obtained her Master of Public Health from the Harvard School of Public Health. Her research aims to decrease barriers and disparities in surgical care, including in low and middle income settings. -
Bruce Ling
Senior Research Scientist, Pediatrics - Neonatology
Current Research and Scholarly InterestsA significant focus of my career is the use of AI to decode real-world datasets of electronic health records, high-resolution LCMS-based liquid/tissue biopsy proteomics/metabolomics, and multiple modality medical imaging.
-
Douglas Liou
Clinical Associate Professor, Cardiothoracic Surgery
BioDr. Liou is a local product, having grown up in Salinas and graduated from U.C. Berkeley with a degree in Molecular and Cell Biology. He received his M.D. from New York Medical College and completed his General Surgery training at Cedars-Sinai Medical Center in Los Angeles. At Cedars, he was recognized for his excellence in clinical care and research with numerous awards and publications. Dr. Liou recently completed his 2 years of Thoracic Surgery training at Stanford, during which time he proved to be an outstanding physician and surgeon and a dedicated clinical researcher.
Dr. Liou’s expertise includes all surgical diseases of the lung, mediastinum, esophagus, chest wall, and diaphragm, with particular interest in thoracic oncology and minimally invasive surgical techniques. He has extensive experience with minimally invasive and open management of lung and esophageal cancer, mediastinal tumors, and benign esophageal disease. Dr. Liou's primary research focus has been on clinical outcomes in thoracic oncology and quality improvement.
Dr. Liou practices out of Stanford Hospital main campus and Stanford Health Care-ValleyCare Hospital in Pleasanton, where he is starting Stanford's Thoracic Surgery program in the East Bay. -
Juliana Liu, MSN, RN, ANP-C
Affiliate, CVI/Vera Moulton Wall Center
BioJuliana Liu, MSN, RN, ANP-C is the Program Manager and Nurse Practitioner for the Adult Pulmonary Hypertension Service at Stanford. She received her Adult Nurse Practitioner (ANP) degree from the University of California, San Francisco School of Nursing. She has a BA in History from Pomona College. Juliana Liu has worked in the Pulmonary Hypertension field since 2002, and has presented at numerous nursing and patient conferences in the US and abroad. She has also served as member and chair on several committees of the Pulmonary Hypertension Association.
-
Kyle Loh
Assistant Professor of Developmental Biology (Stem Cell)
BioHow the richly varied cell-types in the human body arise from one embryonic cell is a biological marvel and mystery. We have mapped how human embryonic stem cells develop into over twenty different human cell-types. This roadmap allowed us to generate enriched populations of human liver, bone, heart and blood vessel cells in a Petri dish from embryonic stem cells. Each of these human cells could regenerate their cognate tissue upon injection into respective mouse models, with relevance to regenerative medicine. In addition to developmental and stem cell biology, we have an emerging interest in exploring deadly biosafety level 4 viruses together with our collaborators.
Kyle attended the County College of Morris and Rutgers, and received his Ph.D. from Stanford (working with Irving Weissman), with fellowships from the Hertz Foundation, National Science Foundation and Davidson Institute for Talent Development. He then continued as a Siebel Investigator, and later, as an Assistant Professor and The Anthony DiGenova Endowed Faculty Scholar at Stanford, where he is jointly appointed in the Department of Developmental Biology and Institute for Stem Cell Biology & Regenerative Medicine. Kyle is a Packard Fellow, Pew Scholar, Human Frontier Science Program Young Investigator and Baxter Foundation Faculty Scholar, and his research has been recognized by the NIH Director's Early Independence Award, Forbes 30 Under 30, Harold Weintraub Graduate Award, Hertz Foundation Thesis Prize and A*STAR Investigatorship. -
Jonathan Z. Long
Associate Professor of Pathology
BioDr. Jonathan Long is an Associate Professor of Pathology and an Institute Scholar of Stanford ChEM-H (Chemistry, Engineering & Medicine for Human Health). His laboratory studies signaling pathways in mammalian energy metabolism. The long-term goal of this program is to discover new molecules and pathways that can be translated into therapeutic opportunities for obesity, metabolic disease, and other age-associated chronic diseases. Work from the laboratory has been recognized by numerous awards from the Alfred P. Sloan Foundation, the National Institutes of Health, the American Diabetes Association, and the Ono Pharma Foundation. Prior to arriving to Stanford, Dr. Long completed his Ph.D. in Chemistry at Scripps Research and his postdoctoral work at Harvard Medical School.
-
Dr. Michael T. Longaker
Deane P. and Louise Mitchell Professor in the School of Medicine and Professor, by courtesy, of Materials Science and Engineering
On Partial Leave from 03/01/2025 To 02/28/2026Current Research and Scholarly InterestsWe have six main areas of current interest: 1) Cranial Suture Developmental Biology, 2) Distraction Osteogenesis, 3) Fibroblast heterogeneity and fibrosis repair, 4) Scarless Fetal Wound Healing, 5) Skeletal Stem Cells, 6) Novel Gene and Stem Cell Therapeutic Approaches.
-
James Longoria, MD
Clinical Associate Professor, Cardiothoracic Surgery
BioDr. Longoria is a board-certified, fellowship-trained cardiothoracic surgeon. He is a clinical associate professor in the Department of Cardiothoracic Surgery at Stanford University School of Medicine.
Deeply accomplished in all facets of complex adult cardiothoracic procedures, Dr. Longoria is a high-volume surgeon with more than 20 years of experience and an exceptionally low mortality and complication rate.
Dr. Longoria’s surgical experience includes complex mitral valve and tricuspid valve repair, coronary artery bypass grafting, adult congenital repair, as well as procedures for high risk VAD patients. He performs cardiac transplantation, carotid endarterectomy, and implantation of all FDA-approved mechanical circulatory support devices. Additionally, he performs catheter-based valvular procedures (such as transcatheter aortic valve replacement, or TAVR) and open and video-assisted thoracoscopic surgery (VATS) for pulmonary surgical procedures.
He has an applied interest in atrial fibrillation (AFib) and is a nationally recognized expert in the minimally invasive surgical treatment of Atrial Fibrillation (AFib). Dr. Longoria was issued a method patent from the U.S. Patent and Trademark Office for developing the TTMaze (Totally Thoracoscopic) procedure that is central to the Dual Epicardial Endocardial Persistent (DEEP) AFib clinical trial.
Before joining Stanford, Dr. Longoria was the surgical director of cardiac ablation at a prominent AFib center certified by the Society of Chest Pain Centers. He holds patents for a synthetic chord used to connect tissue and for specialized methods he developed to treat cardiac arrhythmias.
At Stanford, Dr. Longoria brings a commitment to patientcentric, personalized care. He is committed to making the experience of surgery as pleasant as possible for his patients. He is also excited for the opportunity to conduct translational research that utilizes the most advanced technology available, in collaboration with colleagues from other disciplines.
For his outcomes and high patient satisfaction ratings, Dr. Longoria has earned awards and recognition, including being named a Top Doctor of Sacramento by his peers for the last five years in a row. He has also been an honoree of the President’s Award for patient satisfaction by the Sutter Independent Physicians.
Dr. Longoria has published articles on genetic variants associated with atrial fibrillation, thoracoscopic left atrial appendage clipping, radiofrequency ablation, and other topics. His work has appeared in the Journal of Thoracic and Cardiovascular Surgery, Annals of Thoracic Surgery, Journal of the American College of Cardiology, Journal of Cardiovascular Electrophysiology, and elsewhere.
He has made numerous presentations on atrial fibrillation surgery and other topics at conferences including the Annual Meeting of the American Association of Thoracic Surgery, Society of Thoracic Surgeons, and International Society for Heart and Lung Transplantation.
Dr. Longoria is a Fellow of the American College of Surgeons and American College of Cardiology. He is a member of the Society of Thoracic Surgeons, Western Thoracic Surgical Association, the International Society for Minimally Invasive Cardiothoracic Surgery, and the Heart Rhythm Society. -
Norman Lowenbraun
Member, Cardiovascular Institute
BioDr Lowenbraun has been a practicing cardiologist in the Bay Area for over 25 years, having moved here after receiving his medical and specialty training on the East Coast. He believes offering the personal care of a community setting and empowering the patient in their healthcare decisions, combined with the resources of Stanford Hospital , offers his patients the best of both worlds.
-
George Lui
Clinical Professor, Medicine - Cardiovascular Medicine
Clinical Professor, Pediatrics - CardiologyCurrent Research and Scholarly InterestsAdult Congenital Heart Disease
-
Matthew Lungren
Adjunct Professor, Biomedical Data Science
BioDr. Lungren is Chief Data Science Officer for Microsoft Health & Life Sciences where he focuses on translating cutting edge technology, including generative AI and cloud services, into innovative healthcare applications. As a physician and clinical machine learning researcher, he maintains a part-time clinical practice at UCSF while also continuing his research and teaching roles as adjunct professor at Stanford University.
Prior to joining Microsoft, Dr Lungren was a clinical interventional radiologist and research faculty at Stanford University Medical School where he led the Stanford Center for Artificial Intelligence in Medicine and Imaging (AIMI). He later served as Principal for Clinical AI/ML at Amazon Web Services in World Wide Public Sector Healthcare, focusing on business development for clinical machine learning technologies in the public cloud.
His scientific work has led to more than 150 publications, including work on multi-modal data fusion models for healthcare applications, new computer vision and natural language processing approaches for healthcare specific domains, opportunistic screening with machine learning for public health applications, open medical data as public good, prospective clinical trials for clinical AI translation, and application of generative AI in healthcare. He has served as advisor for early stage startups and large fortune-500 companies on healthcare AI technology development and go-to-market strategy. Dr. Lungren's work has been featured in national news outlets such as NPR, Vice News, Scientific American, and he regularly speaks at national and international scientific meetings on the topic of AI in healthcare.
Dr. Lungren is also a top rated instructor on Coursera where his AI in Healthcare course designed especially for learners with non-technical backgrounds has been completed by more than 20k students around the world - enrollment is open now: https://www.coursera.org/learn/fundamental-machine-learning-healthcare -
Mitchell R. Lunn
Associate Professor of Medicine (Nephrology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsLGBTQIA+ health
-
Michael Ma
Associate Professor of Cardiothoracic Surgery (Pediatric Cardiac Surgery)
Current Research and Scholarly InterestsOur lab aims to understand the biomechanics that govern a wide spectrum of congenital heart defects, and how those biomechanics change with contemporary operative repair strategies. We simulate operations virtually via CFD, and in ex vivo and in vivo animal models, and analyze how the changes we make alter fluid flow, pressure, and stresses throughout the system. We hope that these experiments can impact and optimize existing techniques that translate quickly to the operating room.
-
Sean Mackey, M.D., Ph.D.
Redlich Professor, Professor of Anesthesiology, Perioperative, and Pain Medicine (Adult Pain) and, by courtesy, of Neurology and Neurological Sciences
Current Research and Scholarly InterestsMultiple NIH funded projects to characterize CNS mechanisms of human pain. Comparative effectiveness of cognitive behavioral therapy and chronic pain self-management within the context of opioid reduction (PCORI funded). Single session pain catastrophizing treatment: comparative efficacy & mechanisms (NIH R01). Development and implementation of an open-source learning healthcare system, CHOIR (http://choir/stanford.edu), to optimize pain care and innovative research in real-world patients.
-
Merritt Maduke
Professor of Molecular and Cellular Physiology
Current Research and Scholarly InterestsMolecular mechanisms of ion chnanels & transporters studied by integration of structural and electrophysiological methods.
-
Holden Maecker
Professor (Research) of Microbiology and Immunology
On Partial Leave from 09/15/2024 To 08/31/2025Current Research and Scholarly InterestsI'm interested in immune monitoring of T cell responses to chronic pathogens and cancer, and the correlation of T cell response signatures with disease protection.
-
Kenneth Mahaffey
Professor of Medicine (Cardiovascular Medicine)
BioClinical Focus: Cardiovascular Medicine: Atrial Fibrillation; Chronic CAD; ACS;
Research Focus:
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Associate Dean, Clinical Research School of Medicine; Vice Chair of Clinical Research Department of Medicine; Director Stanford Center for Clinical Research; Member of the Stanford IRB
Professional Training:
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Faculty Cardiovascular Medicine -
Richard D. Mainwaring
Clinical Professor, Cardiothoracic Surgery
Current Research and Scholarly InterestsProfessional Interests: Pediatric cardiovascular surgery, surgery for adults with congenital heart disease
-
Anurag Mairal
Adjunct Professor, Medicine - Cardiovascular Medicine
BioDr. Anurag Mairal is an Adjunct Professor of Medicine and the Director, Global Outreach Programs at Stanford Byers Center for Biodesign, Stanford University. He is also a Faculty Fellow and Lead for Technology Innovation and Impact at Center for Innovation in Global Health. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained se ttings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is founding co-Director for MED 232, Global Health: Scaling Health Technology Innovations in Low Resource Settings, and was part of the founding faculty team for BIOE 371, Global Biodesign: Medical Technology in an International Context, graduate-level courses offered to engineering, business, and medical students at Stanford University. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. He serves as the Founding Chair of BME IDEA APAC, a community of medtech innovation programs in Asia Pacific, partnering closely with the industry and academia in the region. He is also an Honorary Professor at University of Cape Town, South Africa. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry.
Dr. Mairal has an extensive background in medical technology development and commercialization, collaborating with partners in the U.S., India, China, and other emerging markets to advance product development, manufacturing, and distribution. Recently, he took a sabbatical for two years to take a senior leadership role at PATH, a major global health nonprofit based in Seattle. In this role, he oversaw research and development, commercialization, and implementation of technologies in PATH’s medical devices, diagnostics, and digital health divisions. Previously, he held several positions at Johnson & Johnson, including Business Development Director and Product Director for structural heart, cardiology, and peripheral vascular products at Cordis. Before joining J&J, he was a Group Leader and a Process Development Manager at Membrane Technology and Research (MTR). At MTR, he was responsible for business development, strategic alliances, and product development in the bioseparations area. An active mentor to entrepreneurs and industry professionals, he serves as the chair of PATH’s Bay Area Leadership Council; chair of the board at EPPIC Global Network; chair of Faculty Alumni Network at IIT Bombay Heritage Foundation; and President of Sewa International - Bay Area.
Dr. Mairal earned a PhD in chemical engineering from the University of Colorado at Boulder and an MBA from the Haas School of Business at the University of California at Berkeley. He also holds an MS in chemical engineering from the Indian Institution of Technology in Mumbai and a BS in chemical engineering from National Institute of Technology, Raipur. Dr. Mairal was a post-doctoral fellow at the University of Twente, Netherlands and at University of Michigan, Ann Arbor. At BerkeleyHaas, he was a founding co-Chairman of the South Asia Business Conference and Chair of the Biotech Panel for the Asia Business Conference. His work has been published in more than 30 publications, and he has seven issued patents. -
Joshua Makower
Yock Family Professor and Professor of Bioengineering
Current Research and Scholarly InterestsDr. Josh Makower is the Boston Scientific Applied Bioengineering Professor of Medicine and of Bioengineering at the Stanford University Schools of Medicine and Engineering and the Director of the Stanford Byers Center for Biodesign, the program he co-founded with Dr. Paul Yock twenty years ago. Josh helped create the fundamental structure of the Center’s core curriculum and is the chief architect of what is now called “The Biodesign Process.” Over the past 20 years since Josh and Paul founded Biodesign, this curriculum and the associated textbook has been used at Stanford and across the world to train hundreds of thousands of students, faculty and industry leaders on the Biodesign process towards the advancement of medical innovation for the improvement of patient care. Josh has practiced these same techniques directly as the Founder & Executive Chairman of ExploraMed, a medical device incubator, creating 9 companies since 1995. Transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, NC8 and Willow. Josh is also a Special Partner at NEA where he supports the healthcare team and medtech/healthtech investing practice. Josh serves on the boards of Allay Therapeutics, Revelle Aesthetics, Setpoint Medical, DOTS Technologies, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, a bachelor’s degree in Mechanical Engineering from MIT. Josh is a Member of the National Academy of Engineering and the College of Fellows of The American Institute for Medical and Biological Engineering and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.
-
David J. Maron
C. F. Rehnborg Professor and Professor of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsDr. Maron is the Co-Chair and Principal Investigator of the ISCHEMIA trial, and Co-Chair of the ISCHEMIA-CKD trial. These large, international, NIH-funded studies will determine whether an initial invasive strategy of cardiac catheterization and revascularization plus optimal medical therapy will reduce cardiovascular events in patients with and without chronic kidney disease and at least moderate ischemia compared to an initial conservative strategy of optimal medical therapy alone.
-
Alison Marsden
Douglass M. and Nola Leishman Professor of Cardiovascular Diseases, Professor of Pediatrics (Cardiology) and of Bioengineering and, by courtesy, of Mechanical Engineering
Current Research and Scholarly InterestsThe Cardiovascular Biomechanics Computation Lab at Stanford develops novel computational methods for the study of cardiovascular disease progression, surgical methods, and medical devices. We have a particular interest in pediatric cardiology, and use virtual surgery to design novel surgical concepts for children born with heart defects.
-
AC Matin
Member, Cardiovascular Institute
Current Research and Scholarly Interests1. Improvement of our newly discovered cancer prodrug regimen that permits noninvaisve visualization of drug activation. 2. Tracking tumors & cancer metastases using bacterial magnetite and newly developed single-cell tracking by MRI. 3. Molecular basis of bacterial planktonic and biofilm antibiotic resistance on Earth and under space microgravity -- development of new countermeasures; 4. Bioremediation.
-
Michael V. McConnell, MD, MSEE
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsMy imaging research has involved clinical and molecular Imaging of cardiovascular disease, with a focus on coronary and vascular diseases, including atherosclerosis, aortic aneurysms, and vascular inflammation.
My prevention research has involved innovative technologies to reduce coronary and vascular disease, including early disease detection plus leveraging mobile health and AI to enhance heart heart in patients and populations. -
Jessica Lee Mega
Affiliate, Medicine - Med/Cardiovascular Medicine
BioJessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health. She is a Cardiologist at Stanford and serves on the Advisory Board for Stanford's Center for Digital Health. She is a Co-Founder of Alphabet's Verily and former Chief Medical Officer of Google Life Sciences. She is on the Board of Directors at Boston Scientific and Danaher Corporation, as well as the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, Dr. Mega led large, international, randomized trials evaluating novel therapies and new medical technologies. She directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor’s Precision Medicine Initiative.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association (AHA) and the American College of Cardiology (ACC). -
Mark Mercola
Professor of Medicine (Cardiovascular) and, by courtesy, of Chemical and Systems Biology
BioDr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.
Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.
Prof. Mercola received an NIH MERIT award for his work on heart formation. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, Phospholamban Foundation and Fondation Leducq. -
D. Craig Miller, M.D.
Thelma and Henry Doelger Professor of Cardiovascular Surgery, Emeritus
Current Research and Scholarly InterestsCardiac and heart valve disease with experimental laboratory large animal projects focused on the investigation of left ventricular and cardiac mechanics, bioenergetics, and LV and mitral valve physiology and pathophysiology. Current thrust is aimed at understanding the mitral valve and subvalvular mitral apparatus and transmural LV wall strains, thickening, and myolaminar fiber-sheet mechanics.
Clinical research interests include thoracic aortic diseases (aortic dissection, aneurysm) and cardiac valvular disease, including surgical treatment, endovascular thoracic aortic stent-graft repair, mitral valve repair, and valve-sparing aortic root replacement. -
Lloyd B. Minor, MD
The Carl and Elizabeth Naumann Dean of the School of Medicine, Vice President for Medical Affairs, Stanford University, Professor of Otolaryngology - Head and Neck Surgery and Professor of Neurobiology and of Bioengineering, by courtesy
Current Research and Scholarly InterestsThrough neurophysiological investigations of eye movements and neuronal pathways, Dr. Minor has identified adaptive mechanisms responsible for compensation to vestibular injury in a model system for studies of motor learning. Following his discovery of superior canal dehiscence, he published a description of the disorder’s clinical manifestations and related its cause to an opening in the bone covering of the superior canal. He subsequently developed a surgical procedure to correct the problem.
-
R. Scott Mitchell
Professor of Cardiothoracic Surgery at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsResearch Interests: Disease of the aorta, congenital and acquired. Treatment of aortic pathology, including development of stent graft systems. Patterns of disease in patients treated with mediastinal radiation. Valvular heart disease, especially aortopathy associated with congenital bicuspid aortic valve.
-
Edward Mocarski
Professor of Microbiology and Immunology, Emeritus
Current Research and Scholarly InterestsMy research interests focused on the biology and pathogenesis of cytomegalovirus (CMV), an opportunistic pathogen that causes significant disease worldwide, reporting discoveries in areas of CMV gene regulation, DNA replication and packaging, maturation, impact on the host cell, disease pathogenesis, latency and reactivation, host cell death signaling and chemokine system. In the last 20 years of my academic career, we studied viral cell death suppressors and discovered ZBP1-RIPK3 necroptosis.
-
Daria Mochly-Rosen
George D. Smith Professor of Translational Medicine
Current Research and Scholarly InterestsTwo areas: 1. Using rationally-designed peptide inhibitors to study protein-protein interactions in cell signaling. Focus: protein kinase C in heart and large GTPases regulating mitochondrial dynamics in neurodegdenration. 2. Using small molecules (identified in a high throughput screens and synthetic chemistry) as activators and inhibitors of aldehyde dehydrogenases, a family of detoxifying enzymes, and glucose-6-phoshate dehydrogenase, in normal cells and in models of human diseases.
